Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

21.05USD
15 Dec 2017
Change (% chg)

$0.35 (+1.69%)
Prev Close
$20.70
Open
$20.75
Day's High
$21.15
Day's Low
$20.55
Volume
962,102
Avg. Vol
863,292
52-wk High
$33.00
52-wk Low
$13.60

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $984.03
Shares Outstanding(Mil.): 46.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Acorda Resubmits New Drug Application For INBRIJA

* ACORDA RESUBMITS NEW DRUG APPLICATION FOR INBRIJA™ (CVT-301, LEVODOPA INHALATION POWDER)

Dec 07 2017

UPDATE 3-Acorda Therapeutics scraps Parkinson's drug after deaths

* Last week company reported five deaths in tozadenant studies

Nov 20 2017

Acorda Therapeutics scraps Parkinson's drug after deaths

Acorda Therapeutics Inc said on Monday it would stop developing its Parkinson's disease drug, tozadenant, less than a week after the company reported deaths in key studies testing the treatment.

Nov 20 2017

Acorda Therapeutics scraps development of Parkinson's disease drug

Nov 20 Acorda Therapeutics Inc said on Monday it would terminate developing its drug to treat Parkinson's disease, a week after the drugmaker reported five deaths in key studies testing the treatment.

Nov 20 2017

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Nov 17 2017

Acorda reports five deaths in Parkinson's trial, shares plunge

Acorda Therapeutics Inc said five people died in trials for its Parkinson's disease drug, the latest in a series of setbacks for the drugmaker, sending its shares down 38 percent.

Nov 15 2017

UPDATE 4-Acorda reports five deaths in Parkinson's trial, shares plunge

* Shares tank nearly 40 pct (Recasts, adds CEO and analyst comments, updates shares)

Nov 15 2017

BRIEF-Acorda provides update on tozadenant development program

* Identified cases of agranulocytosis, possibly drug-related, in some cases associated with sepsis and death​

Nov 15 2017

Acorda halts enrollment in Parkinson's disease trial

Nov 15 Acorda Therapeutics Inc said on Wednesday it has halted enroling patients in a late-stage trial testing its drug to treat Parkinson's disease, after reports of cases related to neutropenia, sepsis and death.

Nov 15 2017

BRIEF-Acorda Therapeutics reports Q3 non-gaap earnings per share $0.43

* Q3 revenue $141.1 million versus I/B/E/S view $150.6 million

Oct 31 2017

Earnings vs. Estimates